OBI Pharma Enters Licensing Agreement with Novartis for Next-Generation Antibody-Drug Conjugates Worth Over $2 Billion

In The News
November 17, 2026

Ropes & Gray advised Taiwan-based OBI Pharma in a collaboration and license agreement with Novartis Pharma AG in a transaction worth over $2 billion announced on November 13.

Under the agreement, Novartis will receive an exclusive global license to OBI Pharma's antibody-drug conjugates (ADC) platform technologies, patents and know-how for developing next-generation ADC drugs carrying novel payloads. OBI Pharma will receive a $30 million upfront payment, with additional tiered milestone payments to follow, bringing the total potential deal value to more than $2 billion, plus tiered royalties on net sales of licensed products resulting from the collaboration. Novartis also holds an option to expand the collaboration to additional payload classes in the future. 

The Ropes & Gray team was led by life sciences licensing partner Hannah England and associate Nicole Rohr.